Article
A U.S. District Judge has sustained plaintiff's complaint against the manufacturers of the LHRH agonist leuprolide acetate (Lupron), for improper pricing activities.
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
Expert discusses the promise of emerging MISTs for BPH
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk